DHS Working Papers No. 125
Рекомендации ВОЗ по оказанию дородовой помощи для формирования положительного опыта беременности
Key population brief.
Краткое руководство.
Rapport sur les populations clés.
Human Rights, Minimum Standards and Monitoring at the European and International Levels
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
SIAPS Technical Report. This report summarizes key accomplishments and lessons learned in implementing SIAPS’ approach to improving IPC practices in four countries: South Africa, Namibia, Jordan, and Ethiopia. All activities address SIAPS’s overall objective to build or enhance national and faci...lity capacity to develop, implement, and monitor IPC programs by focusing on the principles of health systems strengthening.
more
Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
Epidemiologisches Bulletin; 22. August 2016 / Nr. 33 ;DOI 10.17886/EpiBull-2016-050
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more